|
5/23/2013 8:07:09 AM
|
|
|
5/23/2013 7:03:29 AM
|
Omeros Says Investigational New Drug Application To Evaluate OMS824 In Huntington's Disease Cleared By FDA
|
|
5/14/2013 12:45:51 PM
|
Omeros Corp. Announces Closing Of $16.2 Mln Registered Direct Offering Of Common Stock
|
|
5/10/2013 7:06:59 AM
|
Omeros Q1 Loss/Share $0.40, Same As Last Year
|
|
5/9/2013 6:38:12 PM
|
Omeros Corp. Announces $16.2 Mln Registered Direct Offering Of Common Stock
|
|
5/1/2013 7:43:26 AM
|
|
|
5/1/2013 7:06:24 AM
|
Omeros Says Requests Fast Track Designation From US FDA For Development Of OMS824 For Treatment Of Huntington's Disease
|
|
4/30/2013 10:59:28 PM
|
|
|
4/21/2013 10:49:49 PM
|
|
|
4/17/2013 7:26:42 AM
|
|
|
4/17/2013 7:02:24 AM
|
Omeros Files Orphan Drug Application For OMS721 For Atypical Hemolytic Uremic Syndrome
|
|
4/10/2013 7:03:27 AM
|
Omeros Says GPR17 Antagonists Improve Function In Model Of Multiple Sclerosis
|
|
4/5/2013 8:30:40 AM
|
|
|
4/2/2013 7:50:56 AM
|
|
|
4/2/2013 7:01:47 AM
|
Omeros Reports Positive OMS721 Data In Model Of Thrombotic Microangiopathy
|
|
3/28/2013 7:17:40 AM
|
|
|
3/28/2013 7:06:57 AM
|
Omeros Corp. Announces Data From Toxicology Studies Evaluating OMS721
|
|
3/26/2013 7:37:03 AM
|
|
|
3/26/2013 7:04:09 AM
|
Omeros Reports Positive Data From Phosphodiesterase 10 Phase 1 Multiple Ascending Dose Trial
|
|
3/18/2013 4:34:05 PM
|
|